We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
The purpose of monitoring adults who receive growth hormone (GH) replacement therapy is to allow the gathering of information that will enable the clinician to estimate the benefits and possible side effects of treatment, note whether these are transient or long-term and, if side effects occur, determine how these are best managed. Monitoring allows the clinician to determine the appropriate dose of GH replacement, whether this new and relatively expensive therapy is beneficial to an individual patient and enables a decision regarding the duration of treatment, potentially lifelong, to be made. Before we can be in a position to detect unusual or abnormal situations we must be aware of the normal responses in the adult receiving GH replacement therapy.
Although the number of adults receiving GH replacement therapy is increasing, treatment with GH has been used most extensively in children with GH deficiency (GHD). The efficacy of GH replacement was monitored by measuring the growth response of the child. Usually GH therapy was continued until the epiphyses had fused and growth ceased. Change in growth velocity is a variable that is easy to measure, occurs as a direct response to GH replacement and is inexpensive in terms of financial cost even if based on measurements at three-monthly intervals. Now that adults with GHD, of either childhood or adult onset, are likely to receive GH therapy for many years of their adult life, what parameters should we measure? Should we use a biological end point such as a change in body composition? Not every centre has access to the optimum facilities required to measure this.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.